Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

2007 (EUR 5.0 million in 2006);

- Net loss of EUR 7.3 million, against EUR 4.5 million in 2006; - Cash burn from operations remained limited at EUR 4.9 million (EUR 3.9 million in 2006);

- Consolidated cash and cash equivalents position increased to EUR 31.3 million at December 31, 2007 by issuance of new shares against EUR 24.0 million at December 31, 2006.

- Strategic progress in therapeutics

- New financial commitments from Allergan on the collaboration with the nomination in regulatory pre-development of a second compound resulting from the collaboration.

- Strengthened position in diagnostics

- Initiation of a new program in the field of blood diagnostic of prostate cancers in the framework of the collaboration signed with bioMerieux. To this end, ExonHit has initiated to the financing of clinical trials in Austria to speed the collection of blood samples.

- Development of the SpliceArray(TM) business

- Implementation and certification of an Affymetrix platform to equip a second service laboratory in Paris.

- Strengthened patent portfolio

- 10 new patents were filed in 2007, bringing the total of active patents filed since the Company's creation in 1997 to 177. 26 patents have been granted to ExonHit Therapeutics since its inception.

Bruno Tocque, President of the Management Board of ExonHit, commented: "We have reached our main objectives in 2007. We are very proud of the work accomplished by our collaborators in a context of market agitation which has been very disturbing for companies like ExonHit which invest in innovation with 65% of its operating expenses devoted to R&D.

We have kept our cash burn from operations below EUR 5 million while still investing more in R&D than in 2006. At December 31, 2007, we have an enviable cash and cash equivalent position of EUR 31.3 million. We will thereby have the capacity to continue our investment efforts, and notably in Alzheimer's
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Columbia, Md. (PRWEB) October 21, 2014 ... package, an LC/MS/MS data tool for the pain management ... efficiency of data processing and review by allowing users ... importance to clinicians. , QuantAnalytics allows analysts to ... orders. This expedites data processing by eliminating the need ...
(Date:10/22/2014)... Ras Al Khaimah, UAE (PRWEB) October 22, 2014 ... in game-changing life science and healthcare projects, announces the ... MBBS MRCGP DRCOG DCH to its advisory team. Dr. ... research advisory team. , A graduate of ... Dr. Siddiqui was subsequently degreed in medicine in 2001. ...
(Date:10/22/2014)... Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... next steps for its Oral Amphotericin B program.  ... in vitro work involving samples from ... plans to complete pre clinical studies and regulatory ... 1A clinical trial, utilizing approximately $700,000 of funding ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems ... and Labeling Systems, Table-top Counters) by End-user (Inpatient ... & Trends to 2019” analyzes and studies the ... America, Europe, Asia-Pacific, and the Rest of the ... 30 figures spread through 300 pages and in-depth ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Another Key Regulatory MilestoneLONDON, March 10 Monsanto,s historic ... and biotechnology has contributed to a 24 percent compound ... segment since 2001. This is one of the ... Commercial, will tell investors today as part of a ...
... has long been known for its world-record-breaking carbon ... have discovered new uses by spinning carbon nanotubes ... , Breakthroughs Without Broken Threads ... to grow carbon nanotubes of world-record breaking lengths, ...
... American Pacific Corporation (Nasdaq: APFC ) is ... Chemicals LLC (AFC), located near Sacramento California, recently inaugurated ... The new facility can accommodate either batch reactors (20 ... using up to 7 reactors from 0.25 to 1 ...
Cached Biology Technology:Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 2Monsanto's Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment 3Spinning carbon nanotubes spawns new wireless applications 2AMPAC Fine Chemicals Announces the Inauguration of the New cGMP Continuous Processing Development Facility 2
(Date:10/18/2014)... In a sample of patients with undiagnosed, suspected genetic ... associated with a higher molecular diagnostic yield than traditional ... JAMA . The study is being released to ... meeting. , Exome sequencing, which sequences the protein­coding region ... genetic material present in a cell or organism), has ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
(Date:10/17/2014)... available in German . ... few drugs. When treating overdoses, doctors are often limited to ... if there is a combination of drugs involved. So what ... swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from the ... an answer to this question. "The task was to develop ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... (Santa Barbara, Calif.) Viruses fill the ocean ... marine microbiology, according to a professor of biology at ... Carlson, professor with UCSB,s Department of Ecology, Evolution, and ... of marine viruses published this week by the ...
... transport system inside living cells is a well-oiled machine with ... around the cell. These molecular motors are responsible for a ... on the go. They can put themselves into "energy save ... what gets moved around the cell, and when. ...
... is available in Spanish . A ... what is causing the decline in bumble bee populations and ... the next generation of greenhouse pollinators. Bumble bees, like ... used to pollinate greenhouse crops like peppers and tomatoes. But ...
Cached Biology News:Decade-long study reveals recurring patterns of viruses in the open ocean 2Decade-long study reveals recurring patterns of viruses in the open ocean 3Carnegie Mellon scientists discover how molecular motors go into 'energy save mode' 2Carnegie Mellon scientists discover how molecular motors go into 'energy save mode' 3The flight of the bumble bee: Why are they disappearing? 2
... is an evolutionarily conserved form of cell ... The central component of this process ... caspases. These enzymes participate in a ... response to pro-apoptotic signals and result in ...
... is manufactured for DNA purification from agarose ... UV light. The Purification of DNA from ... DNA-cloning work. The conventional method of visualizing ... UV light damages DNA and significantly decreases ...
...
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Biology Products: